Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

New developments in epilepsy: focus on cenobamate

May 2, 2024

…% reduction) was 50.4% with cenobamate compared to 22.2% with placebo. Long-term data from the pivotal trial by Krauss and colleagues (n=355) were presented at the American Epilepsy Society annual meeting, held December 1-5, 2023, in Orlando, Florida (Nisman et al. AES 2023;P1.31). Results were stratified according to seizure subtype: focal aware motor (FAM) (20.6%), focal impaired awareness (FIA) (89.6%), or focal to bilateral tonic-clonic (FBTC)…

Treatment initiation with a higher-efficacy DMT: update from AAN

April 25, 2024

…. ARR was 0.05 in the continuous ofatumumab group at Year 6. There was near-complete suppression of Gd+ lesions (0.001 lesions/scan) with continuous ofatumumab. The annualized rate of new T2 lesions was also low (0.07). The teriflunomide group saw substantial improvements in all endpoints after switching to ofatumumab. ARR was reduced 71% from 0.228 in the core phase to 0.065; the number of Gd+ lesions/scan was reduced 98% from 0.319 to 0.005; and…

REPORT FROM AAN 2024 – THURSDAY, APRIL 18

April 18, 2024

…oralumab appeared to reduce microglial activation in 5 of 6 patients. White-matter z-scores were reduced 26-36% at three and six months. EDSS scores were stable. A phase II dose-ranging study is now underway (NCT06292923). Higher infection risk with oral DMTs vs. NTZ in MS A retrospective chart review over a 10-year period reported that the incidence of serious infections was significantly higher in patients receiving a fumarate (19.0 per 100 pati…

REPORT FROM AAN 2024 – WEDNESDAY, APRIL 17

April 17, 2024

…15 Edition Cenobamate in focal-onset seizures and refractory epilepsy: real-world data Donanemab in early Alzheimer disease Ocrelizumab efficacy in African-Americans and Hispanics Utility of biomarkers in RIS CONGRESS HIGHLIGHTS – WEDNESDAY EDITION Cenobamate in focal-onset seizures and refractory epilepsy: real-world data Cenobamate was approved by Health Canada last November as an adjunctive therapy for the management of partial-onset seizures i…

REPORT FROM AAN 2024 – TUESDAY, APRIL 16

April 16, 2024

…Information System Short Form-Fatigue-Multiple Sclerosis 8a (PROMIS-Fatigue-MS-8a) tool. MAb exposure during breastfeeding – safety data Animal studies have detected the secretion of monoclonal antibodies in breast milk and patients are generally advised not to receive MAb therapy during breastfeeding. An analysis of the German MS and Pregnancy Registry identified 183 cases in which a patient with MS or NMOSD was exposed to a MAb while breastfeedi…